NEW YORK, Jan. 27, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Novan, Inc. ("Novan" or the "Company") (NASDAQ: NOVN)
The investigation focuses on whether the Company and its executives violated federal securities laws.
Specifically, during pre-market trading on January 27, 2017, the Company announced that Novan's two phase 3 pivotal clinical trials for its topical acne treatment had yielded different results. The Company revealed one trial showed statistical significance for all three co-primary endpoints and the other trial showed significance on only one. On this news, Novan's share price was negatively affected, causing investors harm.
Request more information now by clicking here: www.faruqilaw.com/NOVN. There is no cost or obligation to you.
If you invested in Novan stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/NOVN. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Novan's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novan-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-novan-inc--to-contact-the-firm-300398215.html
SOURCE Faruqi & Faruqi, LLP